Angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor antagonists (AIIRAs) v placebo or no treatment (control)*
| Outcomes at at 6–96 months | Number of trials (n) | Intervention v control | Weighted event rates | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|---|
| *Abbreviations defined in glossary; weighted event rates, RRR, RBI, NNT, and CI calculated from data in article using a random effects model. | |||||
| †NS = not significant. | |||||
| All cause mortality | 20 (2383) | ACE inhibitors | 11.5% v 12.2% | 21% (1 to 37) | 157 (44 to ∞) |
| 5 (3409) | AIIRAs | 15.4% v 15.6% | 1% (−16 to 15) | NS† | |
| Progression from microalbuminuria to macroalbuminuria | 16 (2010) | ACE inhibitors | 11% v 22% | 54% (29 to 70) | 10 (6 to 23) |
| 3 (761) | AIIRAs | 7.1% v 15% | 51% (25 to 68) | 14 (9 to 35) | |
| Doubling of serum creatinine | 3 (3251) | AIIRAs | 18% v 22% | 21% (9 to 31) | 32 (14 to ∞) |
| End stage renal disease | 3 (3251) | AIIRAs | 17% v 19% | 22% (9 to 33) | 37 (16 to ∞) |
| RBI (CI) | NNT (CI) | ||||
| Regression from microalbuminuria to normoalbuminuria | 15 (1888) | ACE inhibitors | 28% v 10% | 202% (83 to 398) | 6 (4 to 10) |
| 2 (670) | AIIRAs | 26% v 18% | 42% (5 to 93) | 13 (8 to 57) | |